267 related articles for article (PubMed ID: 32584876)
21. Risk assessment of supply chain for pharmaceutical excipients with AHP-fuzzy comprehensive evaluation.
Li M; Du Y; Wang Q; Sun C; Ling X; Yu B; Tu J; Xiong Y
Drug Dev Ind Pharm; 2016; 42(4):676-84. PubMed ID: 26288999
[TBL] [Abstract][Full Text] [Related]
22. Are excipients really inert ingredients? A review of adverse reactions to excipients in oral dermatologic medications in Canada.
Noiles K; Vender R
J Cutan Med Surg; 2010; 14(3):105-14. PubMed ID: 20487670
[TBL] [Abstract][Full Text] [Related]
23. Disposition of polyoxyethylated excipients in humans: implications for drug safety and formulation approaches.
Ten Tije AJ; Loos WJ; Verweij J; Baker SD; Dinh K; Figg WD; Sparreboom A
Clin Pharmacol Ther; 2003 Nov; 74(5):509-10. PubMed ID: 14586392
[No Abstract] [Full Text] [Related]
24. A review of Formulations of Commercially Available Antibodies.
Strickley RG; Lambert WJ
J Pharm Sci; 2021 Jul; 110(7):2590-2608.e56. PubMed ID: 33789155
[TBL] [Abstract][Full Text] [Related]
25. The impact of common pharmaceutical excipients on the gut microbiota.
Subramaniam S; Kamath S; Ariaee A; Prestidge C; Joyce P
Expert Opin Drug Deliv; 2023; 20(10):1297-1314. PubMed ID: 37307224
[TBL] [Abstract][Full Text] [Related]
26. Anaphylaxis to excipient mannitol: evidence for an immunoglobulin E-mediated mechanism.
Hegde VL; Venkatesh YP
Clin Exp Allergy; 2004 Oct; 34(10):1602-9. PubMed ID: 15479277
[TBL] [Abstract][Full Text] [Related]
27. Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy.
Price KS; Hamilton RG
Allergy Asthma Proc; 2007; 28(3):313-9. PubMed ID: 17619560
[TBL] [Abstract][Full Text] [Related]
28. Considerations for the Use of Polysorbates in Biopharmaceuticals.
Jones MT; Mahler HC; Yadav S; Bindra D; Corvari V; Fesinmeyer RM; Gupta K; Harmon AM; Hinds KD; Koulov A; Liu W; Maloney K; Wang J; Yeh PY; Singh SK
Pharm Res; 2018 May; 35(8):148. PubMed ID: 29797101
[TBL] [Abstract][Full Text] [Related]
29. Pediatric Safety of Polysorbates in Drug Formulations.
Kriegel C; Festag M; Kishore RSK; Roethlisberger D; Schmitt G
Children (Basel); 2019 Dec; 7(1):. PubMed ID: 31877624
[TBL] [Abstract][Full Text] [Related]
30. Excipients and their use in injectable products.
Nema S; Washkuhn RJ; Brendel RJ
PDA J Pharm Sci Technol; 1997; 51(4):166-71. PubMed ID: 9277127
[TBL] [Abstract][Full Text] [Related]
31. Immediate Hypersensitivity Reactions Caused by Drug Excipients: A Literature Review.
Caballero ML; Quirce S
J Investig Allergol Clin Immunol; 2020 Apr; 30(2):86-100. PubMed ID: 32327401
[TBL] [Abstract][Full Text] [Related]
32. Immediate-type hypersensitivity reaction to Mannitol as drug excipient (E421): a case report.
Calogiuri GF; Muratore L; Nettis E; Casto AM; Di Leo E; Vacca A
Eur Ann Allergy Clin Immunol; 2015 May; 47(3):99-102. PubMed ID: 25951149
[TBL] [Abstract][Full Text] [Related]
33. Vial breakage during freeze-drying: crystallization of sodium chloride in sodium chloride-sucrose frozen aqueous solutions.
Milton N; Gopalrathnam G; Craig GD; Mishra DS; Roy ML; Yu L
J Pharm Sci; 2007 Jul; 96(7):1848-53. PubMed ID: 17299763
[TBL] [Abstract][Full Text] [Related]
34. Biologic-induced urticaria due to polysorbate 20.
Kato M; Oiso N; Uchida S; Yanagihara S; Sano H; Tohda Y; Kawada A
J Dermatol; 2019 Jul; 46(7):e230-e232. PubMed ID: 30758866
[No Abstract] [Full Text] [Related]
35. Polyoxylglycerides and glycerides: effects of manufacturing parameters on API stability, excipient functionality and processing.
Jannin V; Rodier JD; Musakhanian J
Int J Pharm; 2014 May; 466(1-2):109-21. PubMed ID: 24607211
[TBL] [Abstract][Full Text] [Related]
36. Pharmaceutical excipient development: the need for preclinical guidance.
Baldrick P
Regul Toxicol Pharmacol; 2000 Oct; 32(2):210-8. PubMed ID: 11067777
[TBL] [Abstract][Full Text] [Related]
37. Excipients in parenteral formulations: selection considerations and effective utilization with small molecules and biologics.
Rayaprolu BM; Strawser JJ; Anyarambhatla G
Drug Dev Ind Pharm; 2018 Oct; 44(10):1565-1571. PubMed ID: 29863908
[TBL] [Abstract][Full Text] [Related]
38. Pharmaceutical excipients - quality, regulatory and biopharmaceutical considerations.
Elder DP; Kuentz M; Holm R
Eur J Pharm Sci; 2016 May; 87():88-99. PubMed ID: 26699228
[TBL] [Abstract][Full Text] [Related]
39. Excipients in valproic acid syrup may cause diarrhea: a case report.
Veerman MW
DICP; 1990 Sep; 24(9):832-3. PubMed ID: 2260339
[TBL] [Abstract][Full Text] [Related]
40. Safety Assessment of Formulation Vehicles Following Intravitreal Administration in Rabbits.
Aguirre SA; Gukasyan HJ; Younis HS; Huang W
Pharm Res; 2018 Jul; 35(9):173. PubMed ID: 29987391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
